偏頭痛治療薬の世界市場2018-2025

◆英語タイトル:Migraine Drugs Market by Type (Abortive Medicine and Preventive Medicine), Route of Administration (Oral, Injection, and Others), and Distribution Channel (Hospital-based Pharmacies, Retail Pharmacies and Online Pharmacies) - Global Opportunity Analysis and Industry Forecast, 2018-2025
◆商品コード:DATA8102171
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2018年7月
◆ページ数:225
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥590,700見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥709,500見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥989,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Migraine is characterized by a recurrent throbbing headache, which usually lasts from four hours to three days. This occurs on one side of the head, but may spread to both sides. It is often accompanied by vomiting, sensitivity to light or sound, nausea, and disturbed vision in some cases. Migraine is sometimes preceded by an aura that is followed by fatigue. The global migraine drugs market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025.
Rise in awareness among patients for migraine treatment & prevention, rapid increase in female population, and surge in prevalence of migraine drive the growth of the global migraine drugs market. However, side effects associated with migraine drugs limit the market growth. On the contrary, growth opportunities in the developing nations and emerging new therapies for migraine treatment are expected to present opportunities for the market growth during the forecast period.

The report segments the migraine drugs market based on type, route of administration, distribution channel, and region. Based on type, the market is bifurcated into abortive medicine and preventive medicine. Depending on route of administration, it is fragmented into oral, injection, and others. By distribution channel, it is categorized into hospital-based Pharmacies, retail Pharmacies, and online Pharmacies. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS

This report entails a detailed quantitative analysis of the overall market trends from 2017 to 2025 to identify the prevailing opportunities along with strategic assessment of the global migraine drugs market.
Market size and estimations are based on comprehensive analysis of the applications and developments in the industry.
An in-depth analysis based on region is provided to understand the regional market and facilitate the strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Type

Abortive Medicine
Triptans (Serotonin Receptor Agonists)
Ergotamine Derivative
Other
Preventive Medicine
Anticonvulsant
Antidepressant
Beta Blocker
Others

By Route of Administration

Oral
Injection
Others

By Distribution Channel

Hospital-based Pharmacies
Retail Pharmacies
Online Pharmacies

By region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

The list of key players operating in this market includes:

Abbott Laboratories
Allergan Plc.
AstraZeneca
Eisai Co., Ltd.
Endo International Plc.
GlaxoSmithKline Plc.
Impax Laboratories
Johnson & Johnson
Merck & Co.
Pfizer Inc.

The other players included in the value chain analysis (and not included in the report) include:

Novartis International AG
Teva Pharmaceutical Industries Limited
Sanofi SA

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS

1.3.1. List of players profiled in the report

1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016-2018
3.2.3. Market share analysis, 2017

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Increase in prevalence of migraine
3.3.1.2. Growth in female population
3.3.1.3. Rise in awareness among patients towards migraine treatment & prevention

3.3.2. Restraints

3.3.2.1. Side effects of migraine drugs

3.3.3. Opportunities

3.3.3.1. Emerging migraine therapies
3.3.3.2. Growth opportunities in the emerging economies

3.3.4. Impact analyses

CHAPTER 4: MIGRAINE DRUGS MARKET, BY TYPE

4.1. Overview
4.2. Abortive medicines

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Triptans

4.2.2.1.1. Market size and forecast

4.2.2.2. Ergotamine derivatives

4.2.2.2.1. Market size and forecast

4.2.2.3. Other abortive medicines

4.2.2.3.1. Market size and forecast

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Preventive medicines

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Anticonvulsants

4.3.2.1.1. Market size and forecast

4.3.2.2. Antidepressants

4.3.2.2.1. Market size and forecast

4.3.2.3. Beta blockers

4.3.2.3.1. Market size and forecast

4.3.2.4. Other preventive medicines

4.3.2.4.1. Market size and forecast

4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

CHAPTER 5: MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Injection

5.3.1. Market size and forecast, region
5.3.2. Market analysis, by country

5.4. Other routes

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview

6.1.1. Market size and forecast

6.2. Retail pharmacies

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Hospital pharmacies

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Online pharmacies

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: MIGRAINE DRUGS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. migraine drugs market, by type
7.2.2.1.2. U.S. migraine drugs market, by route of administration
7.2.2.1.3. U.S. migraine drugs market, by distribution channel

7.2.2.2. Canada

7.2.2.2.1. Canada migraine drugs market, by type
7.2.2.2.2. Canada migraine drugs market, by route of administration
7.2.2.2.3. Canada migraine drugs market, by distribution channel

7.2.2.3. Mexico

7.2.2.3.1. Mexico migraine drugs market, by type
7.2.2.3.2. Mexico migraine drugs market, by route of administration
7.2.2.3.3. Mexico migraine drugs market, by distribution channel

7.2.3. North America migraine drugs market, by type
7.2.4. North America migraine drugs market, by route of administration
7.2.5. North America migraine drugs market, by distribution channel

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Germany migraine drugs market, by type
7.3.2.1.2. Germany migraine drugs market, by route of administration
7.3.2.1.3. Germany migraine drugs market, by distribution channel

7.3.2.2. France

7.3.2.2.1. France migraine drugs market, by type
7.3.2.2.2. France migraine drugs market, by route of administration
7.3.2.2.3. France migraine drugs market, by distribution channel

7.3.2.3. UK

7.3.2.3.1. UK migraine drugs market, by type
7.3.2.3.2. UK migraine drugs market, by route of administration
7.3.2.3.3. UK migraine drugs market, by distribution channel

7.3.2.4. Italy

7.3.2.4.1. Italy migraine drugs market, by type
7.3.2.4.2. Italy migraine drugs market, by route of administration
7.3.2.4.3. Italy migraine drugs market, by distribution channel

7.3.2.5. Spain

7.3.2.5.1. Spain migraine drugs market, by type
7.3.2.5.2. Spain migraine drugs market, by route of administration
7.3.2.5.3. Spain migraine drugs market, by distribution channel

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe migraine drugs market, by type
7.3.2.6.2. Rest of Europe migraine drugs market, by route of administration
7.3.2.6.3. Rest of Europe migraine drugs market, by distribution channel

7.3.3. Europe migraine drugs market, by type
7.3.4. Europe migraine drugs market, by route of administration
7.3.5. Europe migraine drugs market, by distribution channel

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Japan migraine drugs market, by type
7.4.2.1.2. Japan migraine drugs market, by route of administration
7.4.2.1.3. Japan migraine drugs market, by distribution channel

7.4.2.2. China

7.4.2.2.1. China migraine drugs market, by type
7.4.2.2.2. China migraine drugs market, by route of administration
7.4.2.2.3. China migraine drugs market, by distribution channel

7.4.2.3. India

7.4.2.3.1. India migraine drugs market, by type
7.4.2.3.2. India migraine drugs market, by route of administration
7.4.2.3.3. India migraine drugs market, by distribution channel

7.4.2.4. Australia

7.4.2.4.1. Australia migraine drugs market, by type
7.4.2.4.2. Australia migraine drugs market, by route of administration
7.4.2.4.3. Australia migraine drugs market, by distribution channel

7.4.2.5. South Korea

7.4.2.5.1. South Korea migraine drugs market, by type
7.4.2.5.2. South Korea migraine drugs market, by route of administration
7.4.2.5.3. South Korea migraine drugs market, by distribution channel

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Rest of Asia-Pacific migraine drugs market, by type
7.4.2.6.2. Rest of Asia-Pacific migraine drugs market, by route of administration
7.4.2.6.3. Rest of Asia-Pacific migraine drugs market, by distribution channel

7.4.3. Asia-Pacific migraine drugs market, by type
7.4.4. Asia-Pacific migraine drugs market, by route of administration
7.4.5. Asia-Pacific migraine drugs market, by distribution channel

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil migraine drugs market, by type
7.5.2.1.2. Brazil migraine drugs market, by route of administration
7.5.2.1.3. Brazil migraine drugs market, by distribution channel

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia migraine drugs market, by type
7.5.2.2.2. Saudi Arabia migraine drugs market, by route of administration
7.5.2.2.3. Saudi Arabia migraine drugs market, by distribution channel

7.5.2.3. South Africa

7.5.2.3.1. South Africa migraine drugs market, by type
7.5.2.3.2. South Africa migraine drugs market, by route of administration
7.5.2.3.3. South Africa migraine drugs market, by distribution channel

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA migraine drugs market, by type
7.5.2.4.2. Rest of LAMEA migraine drugs market, by route of administration
7.5.2.4.3. Rest of LAMEA migraine drugs market, by distribution channel

7.5.3. LAMEA migraine drugs market, by type
7.5.4. LAMEA migraine drugs market, by route of administration
7.5.5. LAMEA migraine drugs market, by distribution channel

CHAPTER 8: COMPANY PROFILES

8.1. Abbott Laboratories

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance

8.2. AbbVie Inc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance

8.3. Allergan Plc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. AstraZeneca PLC

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Eisai Co., Ltd.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance

8.6. Endo International Plc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. GlaxoSmithKline Plc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Johnson & Johnson

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance

8.9. Merck & Co., Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance

8.10. Pfizer Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance

TABLE 01. EXPECTED UPCOMING FDA DECISIONS FOR MIGRAINE DRUGS IN 2018
TABLE 02. GLOBAL MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 03. COMMONLY USED ABORTIVE DRUGS FOR MIGRAINE TREATMENT
TABLE 04. ABORTIVE MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 05. ABORTIVE MIGRAINE DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. PREVENTIVE MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 07. PREVENTIVE MIGRAINE DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 08. GLOBAL MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 09. ORAL MIGRAINE DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 10. INJECTABLE MIGRAINE DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 11. MIGRAINE DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2017-2025 ($MILLION)
TABLE 12. GLOBAL MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 13. MIGRAINE DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2017-2025 ($MILLION)
TABLE 14. MIGRAINE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2017-2025 ($MILLION)
TABLE 15. MIGRAINE DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2017-2025 ($MILLION)
TABLE 16. MIGRAINE DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 17. NORTH AMERICA MIGRAINE DRUGS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 18. U.S. MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 19. U.S. MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 20. U.S. MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 21. CANADA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 22. CANADA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 23. CANADA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 24. MEXICO MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 25. MEXICO MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 26. MEXICO MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 27. NORTH AMERICA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 28. NORTH AMERICA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 29. NORTH AMERICA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 30. EUROPE MIGRAINE DRUGS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 31. GERMANY MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 32. GERMANY MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 33. GERMANY MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 34. FRANCE MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 35. FRANCE MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 36. FRANCE MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 37. UK MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 38. UK MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 39. UK MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 40. ITALY MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 41. ITALY MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 42. ITALY MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 43. SPAIN MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 44. SPAIN MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 45. SPAIN MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 46. REST OF EUROPE MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 47. REST OF EUROPE MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 48. REST OF EUROPE MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 49. EUROPE MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 50. EUROPE MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 51. EUROPE MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 52. ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 53. JAPAN MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 54. JAPAN MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 55. JAPAN MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 56. CHINA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 57. CHINA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 58. CHINA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 59. INDIA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 60. INDIA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 61. INDIA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 62. ITALY MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 63. AUSTRALIA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 64. AUSTRALIA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 65. SOUTH KOREA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 66. SOUTH KOREA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 67. SOUTH KOREA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 71. ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 72. ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 73. ASIA-PACIFIC MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 74. LAMEA MIGRAINE DRUGS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 75. BRAZIL MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 76. BRAZIL MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 77. BRAZIL MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 78. SAUDI ARABIA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 79. SAUDI ARABIA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 80. SAUDI ARABIA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 81. SOUTH AFRICA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 82. SOUTH AFRICA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 83. SOUTH AFRICA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 84. REST OF LAMEA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 85. REST OF LAMEA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 86. REST OF LAMEA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 87. LAMEA MIGRAINE DRUGS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 88. LAMEA MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 89. LAMEA MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 90. ABBOTT: COMPANY SNAPSHOT
TABLE 91. ABBOTT: OPERATING SEGMENTS
TABLE 92. ABBOTT: PRODUCT PORTFOLIO
TABLE 93. ABBVIE: COMPANY SNAPSHOT
TABLE 94. ABBVIE: OPERATING SEGMENTS
TABLE 95. ABBOTT: PRODUCT PORTFOLIO
TABLE 96. ALLERGAN: COMPANY SNAPSHOT
TABLE 97. ALLERGAN: OPERATING SEGMENTS
TABLE 98. ALLERGAN: PRODUCT PORTFOLIO
TABLE 99. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 100. ASTRAZENECA: OPERATING SEGMENTS
TABLE 101. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 102. EISAI: COMPANY SNAPSHOT
TABLE 103. EISAI: OPERATING SEGMENTS
TABLE 104. EISAI: PRODUCT PORTFOLIO
TABLE 105. ENDO: COMPANY SNAPSHOT
TABLE 106. ENDO: OPERATING SEGMENTS
TABLE 107. ENDO: PRODUCT PORTFOLIO
TABLE 108. GSK: COMPANY SNAPSHOT
TABLE 109. GSK: OPERATING SEGMENTS
TABLE 110. GSK: PRODUCT PORTFOLIO
TABLE 111. J&J: COMPANY SNAPSHOT
TABLE 112. J&J: OPERATING SEGMENTS
TABLE 113. J&J: PRODUCT PORTFOLIO
TABLE 114. MERCK: COMPANY SNAPSHOT
TABLE 115. MERCK: OPERATING SEGMENTS
TABLE 116. MERCK: PRODUCT PORTFOLIO
TABLE 117. PFIZER: COMPANY SNAPSHOT
TABLE 118. PFIZER: OPERATING SEGMENTS
TABLE 119. PFIZER: PRODUCT PORTFOLIO

FIGURE 01. MIGRAINE DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2017
FIGURE 04. IMPACT ANALYSES
FIGURE 05. TRIPTANS MARKET, 2017-2025 ($MILLION)
FIGURE 06. ERGOTAMINE DERIVATIVES MARKET, 2017-2025 ($MILLION)
FIGURE 07. OTHER ABORTIVE MIGRAINE DRUGS MARKET, 2017-2025 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF ABORTIVE MIGRAINE DRUGS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 09. MIGRAINE DRUGS MARKET FOR ANTICONVULSANTS, 2017-2025 ($MILLION)
FIGURE 10. MIGRAINE DRUGS MARKET FOR ANTIDEPRESSANTS, 2017-2025 ($MILLION)
FIGURE 11. MIGRAINE DRUGS MARKET FOR BETA BLOCKERS, 2017-2025 ($MILLION)
FIGURE 12. MIGRAINE DRUGS MARKET FOR OTHER PREVENTIVE MEDICINES, 2017-2025 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF PREVENTIVE MIGRAINE DRUGS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF ORAL MIGRAINE DRUGS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF INJECTABLE MIGRAINE DRUGS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF MIGRAINE DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF MIGRAINE DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF MIGRAINE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF MIGRAINE DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2017 & 2025 (%)
FIGURE 20. FREQUENCY OF ADULTS SUFFERING FROM HEADACHES IN U.S., 2017, BY GENDER
FIGURE 21. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 22. ABBOTT: NET SALES SHARE BY OPERATING SEGMENT, 2017 (%)
FIGURE 23. ABBOTT: NET SALES SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 24. ABBVIE: NET SALES, 2015-2017 ($MILLION)
FIGURE 25. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. ALLERGAN: REVENUE, 2015-2017 ($MILLION)
FIGURE 28. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. ASTRAZENECA: REVENUE, 2015-2017 ($MILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. EISAI: REVENUE, 2015-2017 ($MILLION)
FIGURE 32. EISAI: REVENUE BY SEGMENT, 2017 (%)
FIGURE 33. REVENUE, 2015-2017 ($MILLION)
FIGURE 34. ENDO: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. GSK: REVENUE, 2015-2017 ($MILLION)
FIGURE 36. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 37. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. J&J: REVENUE, 2015-2017 ($MILLION)
FIGURE 39. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 42. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 43. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 44. PFIZER: REVENUE, 2015-2017 ($MILLION)
FIGURE 45. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 46. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[偏頭痛治療薬の世界市場2018-2025]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆